EE105 Triamcinolone Acetonide Injectable Suspension, for Suprachoroidal Use, for the Treatment of Macular Edema Associated with Uveitis in the United States: A Budget Impact Analysis

S Bhattacharyya,Sm Hariprasad,Ta Albini,D John,Sk Dutta,B Cohen,Aa Dashputre,D Harrison,G Joseph

doi:10.1016/j.jval.2022.04.358

EE105 Triamcinolone Acetonide Injectable Suspension, for Suprachoroidal Use, for the Treatment of Macular Edema Associated with Uveitis in the United States: A Budget Impact Analysis

S Bhattacharyya, Sm Hariprasad + Show 7 more

Open Access

https://doi.org/10.1016/j.jval.2022.04.358

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Jun 25, 2022
License type: publisher-specific-oa

Affiliation: University of Chicago, Ocular Surface Center, Postnova Analytics (United States), Bausch Health (United States)

#Triamcinolone Acetonide Injectable Suspension #Macular Edema + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Triamcinolone acetonide injectable suspension, for suprachoroidal use, has recently received FDA approval to treat macular edema (ME) associated with uveitis (specifically non-infectious uveitis; NIU) in the US. The objective of this study was to assess the budget impact of the drug for the treatment of ME associated with NIU from a US third-party payer perspective (Commercial and Medicare).

Full Text